This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Nasacort AQ

Sanofi

Drug Names(s): Nasacort Allergy 24 HR, triamcinolone actonide

Description: Nasacort AQ is an aqueous-based (AQ) corticosteroid nasal spray that contains triamcinolone acetonide.

Deal Structure: Nasacort AQ was originally developed by Rhone-Poulenc Rorer Pharmaceuticals.

In January 1999, Rhone-Poulenc merged with Hoechst to form Aventis.

In 2004, Aventis merged with Sanofi-Synthelabo to form Sanofi-Aventis.


Nasacort AQ News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug